- Theriva Biologics closes sale of SYN-004 enzyme portfolio to Biossil Labs.
- Receives $350K upfront with eligibility for up to $91M in regulatory and sales milestones plus royalties.
- Biossil assumes all future development and commercialization expenses.
?? Positive AI Sentiment (+2.5 / 10)